Acurx Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Acurx Pharmaceuticals

15/03/2024 12:37

* Acurx Pharmaceuticals Inc  ACXP.OQ   ACXP.O  is expected
to show
no change in quarterly revenue when it reports  results on March
18 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Acurx Pharmaceuticals
Inc is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acurx
Pharmaceuticals Inc is $13.18​, above​ its last closing price
of $2.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.28       -0.27      -0.24     Beat    11.1
 Jun. 30 2023  -0.27       -0.27      -0.28     Missed  -3.7
 Mar. 31 2023  -0.30       -0.29      -0.25     Beat    15.3​
 Dec. 31 2022  -0.35       -0.35      -0.28     Beat    20
 ​​Sep.        -0.27       -0.28      -0.32     Missed  -14.3
 30 2022                                                
                                                        ​
 Mar. 31 2022              -0.33      -0.26     Beat    21.2
 Dec. 31 2021  -0.40       -0.40      -0.22     Beat    45
 This summary was machine generated March 15 at 12:36 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)